Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
62 Results for "
BTB
" in MedChemExpress (MCE) Product Catalog:
Products (62)
62 Results for "BTB" in MCE Product Catalog:
3
3 Cited Publications
Target:
Research Areas:
BI-3802, a chemical probe, is a highly potent BCL6 degrader and inhibits the Bric-à-brac (BTB) domain of BCL6 with an IC50 of ≤3 nM. BI-3802 induces the polymerization of BCL6 and promotes BCL6 degration depended on E3 ligase SIAH1. BI-3802 has antitumor activity .
3
3 Cited Publications
BI-3812, a chemical probe, is a highly efficient BCL6 inhibitor that is capable of suppressing the BTB domain of BCL6, with an IC50 value of ≤ 3 nM, exhibiting antitumor activity .
2
2 Cited Publications
Target:
Research Areas:
BTB06584 is a selective and IF1-dependent mitochondrial F1Fo-ATPase inhibitor without compromising ATP synthesis. BTB06584 can delays ischaemic cell death .
2
2 Cited Publications
Target:
Research Areas:
BTB-1 is a potent, selective and reversible mitotic motor protein Kif18A inhibitor with an IC50 of 1.69 μM.
2
2 Cited Publications
Cat. No.: HY-P1848
CAS No.: 395069-86-0
Target:
Research Areas:
1
1 Cited Publications
Target:
Research Areas:
BTB09089 is a T cell death-associated gene 8 (TDAG8/GPR65) specific agonist. BTB09089 increases TDAG8 expression and regulates the cytokine production of T cells and macrophages .
Cat. No.: HY-172736
CAS No.: 3005272-36-3
Synonyms: BMS-986458
Toviblideg (BMS-986458) is a highly selective, orally active cereblon-based BCL6 PROTAC degrader and antitumor agent. Toviblideg selectively degrades BCL6 by binding cereblon to the BTB domain of BCL6, thereby regulating the cell cycle, antiproliferative and interferon signaling pathways, and upregulating the expression and distribution of CD20. Toviblideg modulates the phenotype of follicular helper T cells and reduces circulating tumor DNA levels. The combination of Toviblideg with CD20xCD3 bispecific antibody also enhances the efficiency of T cell tumor infiltration and expansion. Toviblideg induces regression of BCL6-positive tumors and prolongs survival, and it is suitable for research related to B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and relapsed/refractory lymphoma .
Cat. No.: HY-161138
WK369 is a novel BCL6 small molecule inhibitor, which exhibits excellent anti-ovarian cancer bioactivity, induces cell cycle arrest and causes apoptosis. WK369 can directly bind to the BCL6-BTB domain and block the interaction between BCL6 and SMRT, leading to the reactivation of p53, ATR and CDKN1A .
Cat. No.: HY-P991571
Synonyms: GC-1118A
Cat. No.: HY-177755
CAS No.: 2230406-52-5
Target:
Research Areas:
BCL6-IN-10 is a molecular glue inhibitor targeting the BCL6 BTB domain with an IC50 of 4 nM. BCL6-IN-10 blocks the interaction between BCL6 and transcriptional co-repressors, and induces partial degradation of BCL6 via the ubiquitin-proteasome pathway, thereby de-repressing BCL6 target genes and inhibiting cancer cell proliferation. BCL6-IN-10 can be used in the research of diffuse large B-cell lymphoma .
Cat. No.: HY-177756
CAS No.: 2230406-60-5
BCL6-IN-11 is a potent inhibitor of the BCL6 BTB domain and a partial degrader of BCL6. BCL6-IN-11 inhibits the interaction between the BCL6 BTB domain and BCOR with an IC50 of 6 nM. BCL6-IN-11 can be used for research related to BCL6 degradation in diffuse large B-cell lymphoma (DLBCL) .
Cat. No.: HY-160509
CAS No.: 652967-47-0
Target:
Research Areas:
BTB 06061 is a TRPM7 inhibitor and can be used for study of ischemic disease .
Cat. No.: HY-153691
CAS No.: 652129-89-0
BTB01303 is a (glutamate release) inhibitor. Cancer cells release high levels of (glutamate), which disrupts normal bone turnover and may lead to cancer-induced bone pain. BTB01303 has the potential to improve cancer-induced bone pain .
Cat. No.: HY-P10543
CAS No.: 857026-08-5
Cat. No.: HY-170301
Target:
Research Areas:
Keap1-IN-1 (Compound 27) is the inhibitor for Keap1, that covalently modifys the Cys151 site in the BTB domain of KEAP1, and interfers with the interaction between Keap-Nrf. Keap1-IN-1 upregulates the mRNA expression of the antioxidant stress element (ARE)-dependent gene NQO1 with an EC50 of 160 nM. Keap1-IN-1 exhibits cytotoxicity in cell U2OS with an EC50 of 527 nM .
Cat. No.: HY-101770R
CAS No.: 86030-08-2
Research Areas:
BTB-1 (Standard) is the analytical standard of BTB-1 (HY-101770). This product is intended for research and analytical applications. BTB-1 is a potent, selective and reversible mitotic motor protein Kif18A inhibitor with an IC50 of 1.69 μM.
Cat. No.: HY-P701536
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: ABTB3; BTB (POZ) Domain Containing 11; Prev. BTBD11; FLJ33957; ABTB2B; Ankyrin Repeat And BTB/POZ Domain-Containing Protein BTBD11; Ankyrin Repeat- And BTB/POZ Domain-Containing Protein 3; Ankyrin Repeat And BTB/POZ Domain-Containing Protein 3; BTB/POZ Do
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P701537
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: ABTB3; BTB (POZ) Domain Containing 11; Prev. BTBD11; FLJ33957; ABTB2B; Ankyrin Repeat And BTB/POZ Domain-Containing Protein BTBD11; Ankyrin Repeat- And BTB/POZ Domain-Containing Protein 3; Ankyrin Repeat And BTB/POZ Domain-Containing Protein 3; BTB/POZ Do
Species:
Human
Source:
Sf9 insect cells
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
